Clinical Trial Update: Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 prospective evaluation of Gallium-68 FAPI PET/MRI in hepatocellular carcinoma, currently recruiting at a single center.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• 68Ga-FAPI PET/MRI tracer (Gallium-68 fibroblast activation protein inhibitor)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: RECRUITING